Researchers screened 308 patients who met clinical criteria for familial hypercholesterolemia but lacked identifiable pathogenic variants in canonical genes. The cohort comprised mutation-negative, clinically confirmed FH cases; the source did not provide further demographic breakdown or selection criteria beyond this description. Peripheral blood genomic DNA was the sample type used for methylation analysis.
The study sought to determine whether constitutional promoter hypermethylation of LDLR at a previously described differentially methylated region could explain some mutation-negative FH diagnoses. Prior large-scale methylation surveys had flagged a locus in the LDLR promoter, prompting this targeted follow-up in a clinically ascertained FH cohort.
Investigators used Combined Bisulfite Restriction Analysis (COBRA) to measure methylation. The assay specifically interrogated TaqI restriction sites within a 332 base-pair segment of the LDLR promoter. The source did not report additional technical parameters such as bisulfite conversion controls, assay sensitivity thresholds, or replicate testing frequency. Blood-derived genomic DNA was the only matrix described.
COBRA detects methylation by combining bisulfite conversion with restriction enzyme digestion; it provides a locus-specific readout but does not offer genome-wide context. The authors confined their analysis to the single previously implicated promoter region rather than surveying adjacent regulatory elements or other CpG sites across the gene.
No instances of promoter hypermethylation at the assayed LDLR locus were detected among all 308 patients screened. The investigators therefore observed a zero-event outcome for this specific epimutation in this cohort. Using Clopper–Pearson statistics, the team calculated an upper prevalence bound of 1.19% (95% confidence interval) for this epimutation within the studied population.
That confidence bound expresses the maximum plausible prevalence consistent with the sample size and the observed null result; it does not quantify methylation elsewhere or at other regulatory sites. The authors reported the figure as evidence that this particular promoter hypermethylation event is uncommon among mutation-negative FH patients.
The data indicate that constitutional hypermethylation of the tested LDLR promoter segment is unlikely to account for a substantial fraction of mutation-negative FH cases. Investigators reported that this specific locus did not show epimutational events in the screened cohort. Clinicians and geneticists assessing unexplained hypercholesterolemia should therefore consider other genetic or epigenetic mechanisms when genetic testing for LDLR, APOB, and PCSK9 returns negative results.
Because the assay targeted a single promoter region, the absence of detected methylation does not rule out epigenetic regulation at other sites in LDLR or at distal regulatory elements. The method also provides no direct measure of LDLR transcript level or protein function in these samples; the source did not present expression or functional follow-up studies.
The authors enumerated several non-mutually exclusive possibilities that may explain the diagnostic gap in FH. These include methylation in other genomic regions not assayed by this study, cumulative effects of common alleles contributing polygenic risk, structural variants that escape standard sequencing pipelines, and non-canonical regulatory mutations beyond the promoter segment tested. The report did not attempt to quantify the contribution of these alternative mechanisms.
Key unanswered questions remain. How often does methylation occur at other LDLR regulatory elements? What proportion of mutation-negative FH is attributable to polygenic risk scores versus undetected structural variants? Do non-promoter regulatory mutations alter LDLR expression in a clinically meaningful way? The present data cannot answer these issues because the study design was narrowly focused and did not include genome-wide methylation, copy-number analysis, or transcriptomic profiling.
The research received Institutional Review Board approval from the Icahn School of Medicine at Mount Sinai (STUDY-22-01301; October 24, 2022), and informed consent was obtained from participants. The authors declared no competing interests. Funding for the work was reported from the National Institute on Aging (AG075051). Data generated in the study are available on reasonable request to the authors; the source did not provide a public dataset link in the preprint.
Limitations documented by the study team include the narrow genomic target (a single 332 bp promoter region) and the absence of functional expression data linking methylation status to LDLR activity. The next steps implied by the authors—though not prespecified as concrete milestones in the source—are systematic searches for methylation at other loci, comprehensive structural-variant screening, and integration of polygenic risk assessment to clarify the remaining diagnostic gap in mutation-negative FH.